38923-57-8

Usage

Uses

Pyrimidine was synthesis from methyl 2, 2-dimethylacetoacetate.

Synthesis Reference(s)

Synthetic Communications, 12, p. 829, 1982 DOI: 10.1080/00397918208065959

InChI:InChI=1/C7H12O3/c1-5(8)7(2,3)6(9)10-4/h1-4H3

Upstream product

• 909874-50-6 2,2'-dimethyl-3,3'-ethanediyldiamino-di-crotonic acid dimethyl ester 
• 74-88-4 methyl iodide 
• 62936-03-2 3-Oxo-2,2-dimethyl-dithiobuttersaeure-methylester 
• 25344-09-6 dimethyl-2,2 oxo-3 thiolbutanoate de methyle 
• 112818-16-3 methyl 2-(iodomethyl)-2-methyl-3-oxobutanoate 
• 64-19-7 acetic acid 
• 105-45-3 acetoacetic acid methyl ester 
• 563-80-4 3-methyl-butan-2-one 
• 17094-21-2 2-methyl-acetoacetic acid methyl ester 
• 23426-63-3 2-bromo-2-methylpropionic acid methyl ester 
• 7487-94-7 mercury (II) chloride 
• 141-52-6 sodium ethanolate 
• 141-97-9 ethyl acetoacetate 
• 74-83-9 methyl bromide 

Downstream Products

• 103-79-7 1-phenyl-acetone 
• 56663-74-2 methyl 3-chloro-2,2-dimethylbut-3-enoate 
• 79902-87-7 2,2-Dimethyl-3-phenylsilanyloxy-butyric acid methyl ester 
• 79891-91-1 3-[(2-Methoxycarbonyl-1,2-dimethyl-propoxy)-phenyl-silanyloxy]-2,2-dimethyl-butyric acid methyl ester 
• 547-63-7 Methyl isobutyrate 
• 60-35-5 acetamide 
• 563-83-7 ISOPROPYLAMIDE 
• 1198227-67-6 C₂₁H₃₄O₆Si 
• 95924-34-8 2,2-dimethyl-3-butynoic acid methyl ester 
• 56663-75-3 2,2-dimethyl-3-chloro-3-butenoic acid 
• 952665-08-6 methyl 4-(2-amino-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 
• 952665-09-7 methyl 4-(2-butyramido-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 
• 1261121-63-4 (5S)-6-benzyl-8,8-dimethyl-1-oxa-3-phenyl-2,6-diazaspiro[4.4]non-2-ene-7,9-dione 
• 1261121-64-5 (5R)-ethyl 6-benzyl-8,8-dimethyl-7,9-dioxo-1-oxa-2,6-diazaspiro[4.4]non-2-ene-3-carboxylate 

Relevant academic research and scientific papers

Process for the alkylation of active methylene compounds

The invention discloses an alkylation method of an active methylene compound. The method comprises the following steps: A, adding the active methylene compound to an inorganic alkali-first polar organic solvent mixing system to form a to-be-reacted mixture; B, adding an alkylating agent to the to-be-reacted mixture, filtering after reacting to obtain filtrate, and removing a solvent in the filtrate to obtain the alkylated active methylene compound. According to the method, the inorganic alkali is adopted as a proton abstraction reagent of the active methylene compound, so that the removal effect on alpha-hydrogen in the active methylene compound can be ensured, the alkylation reaction of the active methylene compound can be carried out under a mild condition, and the reaction safety is improved. Meanwhile, the inorganic alkali is low in price, so that the production cost of the alkylation reaction is reduced.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

PYRROLOPYRIDAZINE JAK3 INHIBITORS AND THEIR USE FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES

Disclosed are compounds of formula (I) and pharmaceutically acceptable salts thereof. The compounds of formula (I) inhibit tyrosine kinase activity of JAK3, thereby making them useful for the treatment of inflammatory and autoimmune diseases.

Novel isoxazolinyl spiropyrrolidinediones: 1,3-dipolar cycloaddition of 1-benzyl-3,3-dimethyl-5-methylenepyrrolidin-2,4-dione

A simple and highly efficient methodology for the first synthesis of isoxazolinyl spiropyrrolidinedione starting from keto ester, is presented. Georg Thieme Verlag Stuttgart - New York.

Titanium silicates as efficient catalyst for alkylation and acylation of silyl enol ethers under liquid-phase conditions

The activity of titanium- and tin-silicate samples such as TS-1, TS-2, Ti-β and Sn-MFI has been investigated for acylation and alkylation of silyl enol ethers under mild liquid-phase conditions. Silyl enol ethers successfully react with acetyl chloride and tert-butyl chloride under dry conditions in the presence of above catalysts to produce the corresponding acylated and alkylated products, respectively. In the case of acetylation reaction, two different nucleophiles with carbon-center (C-atom) and oxygen-center (O-atom) in silyloxy group of silyl enol ether reacts with acetyl chloride to give 1,3-diketone and ketene-ester, respectively. The selectivity for alkylation is always ca. 100% and no side products are formed. Among the various solvents investigated, anhydrous THF was found to be the suitable solvent for alkylation; whereas dichloromethane exhibited high selectivity for diketones for acylation. The formation of nucleophiles from silyl enol ethers appears to be the key step for successful acetylation and tert-butylation by nucleophilic reaction mechanism. Sn-MFI showed less activity than that observed over the titanosilicates. The observed catalytic activity is explained on the basis of "oxophilic Lewis acidity" of titanium silicate molecular sieves in the absence of H 2O under dry reaction conditions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Retroviral protease inhibitors

N-heterocyclic moiety-containing hydroxyethylamine protease inhibitor compounds, methods for making the compounds, and intermediates useful in the method. Also, a method for inhibiting retroviral proteases and for treatment or prophylaxis of a retroviral infection.

Succinoylamino hydroxyethylamino sulfonyl urea derivatives useful as retroviral protease inhibitors

Succinoylamino hydroxyethylamino sulfonyl urea derivatives of the formula: wherein the substituents are as defined in the specification, are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease.